Psychology Research, June 2025, Vol. 15, No. 6,
doi:10.17265/2159-5542/2025.06.002

Dopaminergic Susceptibility and Oxidative Stress: Mechanisms Contributing to Parkinson's Disease

Xiyue Zhang
Simon Fraser University, Burnaby, Canada

Parkinson's disease (PD) features selective degeneration of substantia nigra pars compacta (SNpc) dopaminergic neurons, whose vulnerability is linked to chronic oxidative stress (OS). Dopamine metabolism, mitochondrial dysfunction, iron dysregulation, neuroinflammation, and impaired proteostasis converge to generate a self-reinforcing oxidative loop. This paper synthesizes peer-reviewed evidence on how dopamine's redox chemistry, mitochondrial energetics, and inflammatory processes interact to drive neuronal injury. Figure 1 illustrates the oxidative cascade from dopamine oxidation to mitochondrial collapse, lipid peroxidation, and glial activation. Understanding these mechanisms clarifies how PD evolves as a system-level disorder where interdependent oxidative, metabolic, and disruptions amplify one another.

Keywords: Parkinson's Disease, Oxidative Stress, Dopamine, Iron, Protein, Interconnection and Mutual Reinforcement

Introduction

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide and remains without a proven disease-modifying therapy (Poewe et al., 2017). Clinical symptoms-bradykinesia, rigidity, tremor, and non-motor features reflect extensive dopaminergic system disruption (Chaudhuri & Schapira, 2009). The hallmark neuropathology involves loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and intracellular Œ±-synuclein inclusions known as Lewy bodies. Recent research indicates that the selective vulnerability of these neurons arises from intrinsic metabolic and redox stresses (Dias, Junn, & Mouradian, 2013; Hwang, 2013; Zhou, Tan, & Lim, 2023).



Xiyue Zhang, Bachelor of Arts, Department of Psychology, Simon Fraser University, Burnaby, Canada.

Figure 1. The oxidative stress cascade in dopaminergic neurons. Dopamine oxidation, mitochondrial dysfunction, iron catalysis, and protein misfolding form an interconnected feedback network leading to neuronal degeneration.

The Neurochemical Vulnerability of Dopaminergic Neurons

Dopaminergic neurons in the SNpc possess unique physiological and biochemical traits that make them highly sensitive to oxidative stress (OS). Their autonomous pacemaking activity requires constant calcium influx, leading to elevated mitochondrial workload and reactive oxygen species (ROS) production (Lin & Beal, 2006; Exner, Lutz, Haass, & Winklhofer, 2012). These neurons also have relatively low antioxidant reserves and are rich in cytosolic dopamine, which can auto-oxidize under oxidative conditions. High iron concentrations and low buffering capacity further intensify their vulnerability (Dexter et al., 1989). Collectively, these features create a "perfect redox storm", where energy metabolism and dopamine chemistry continuously interact to generate reactive oxygen species (ROS) and reactive nitrogen species (RNS).

Dopamine Chemistry and the Burden of Redox Instability

Dopamine itself is a potent generator of oxidative load through enzymatic and spontaneous reactions. Monoamine oxidase-B (MAO-B) metabolizes dopamine to dihydroxyphenyl acetic acid (DOPAC), releasing hydrogen peroxide (H,ÇÇO,ÇÇ) (Tan et al., 2022). In the presence of catalytic iron, H,ÇÇO,ÇÇ forms hydroxyl radicals via Fenton reactions, initiating lipid and protein oxidation. Simultaneously, dopamine auto-oxidation yields quinones and semiquinones that covalently modify cysteine-rich proteins such as parkin and DJ-1, impairing antioxidant function (Dias et al., 2013; Chang & Chen, 2020).

Mitochondrial Dysfunction as an Energetic Amplifier of Oxidative Injury

Mitochondria are both targets and amplifiers of oxidative injury in PD. Complex I deficiency is a consistent finding in PD postmortem studies and toxin models (Exner et al., 2012). Impaired electron transport increases electron leak and superoxide generation, while decreased Adenosine triphosphate (ATP) production compromises calcium buffering. Excess calcium entry through L-type channels induces opening of the mitochondrial permeability transition pore (mPTP), collapsing membrane potential and releasing cytochrome c to trigger apoptosis (Lin & Beal, 2006).

Iron Overload and the Lipid-Peroxidation Feedback Loop (Ferroptosis)

Iron homeostasis disruption is another defining biochemical abnormality in PD. The SNpc accumulates iron with aging, and PD brains show significantly increased ferric and ferrous iron levels (Dexter et al., 1989). Excess iron catalyzes Fenton chemistry, converting H,ÇÇO,ÇÇ into hydroxyl radicals that attack membrane polyunsaturated fatty acids (PUFAs), producing toxic aldehydes such as (Qin et al., 2007) 4-hydroxy 2-nonenal (HNE).

Protein Misfolding and the Breakdown of Proteostasis

Oxidative modifications to Œ±-synuclein and key proteostasis regulators create a bridge between redox stress and protein aggregation. Dopamine quinones and lipid peroxidation products (e.g., HNE) can covalently modify Œ±-synuclein, promoting its oligomerization (Hwang, 2013; Zhou et al., 2023).

Interconnection and Mutual Reinforcement Among Pathways

Beyond isolated mechanisms, the interplay among dopamine oxidation, mitochondrial dysfunction, iron dysregulation, and protein misfolding defines the systemic vulnerability of dopaminergic neurons in Parkinson's disease (PD). Each of these stressors can initiate oxidative damage independently, but their convergence forms a

self-propagating feedback network that transforms transient redox imbalance into irreversible neurodegeneration (Chang & Chen, 2020; Dias et al., 2013; Exner et al., 2012; Dong-Chen et al., 2023). This interdependence explains why clinical manifestations of PD-motor slowing, rigidity, tremor, affective flattening, and cognitive decline cannot be attributed to a single biochemical lesion but rather to cascading interactions within the dopaminergic system and its metabolic milieu (Poewe et al., 2017; Zhou et al., 2023).

Dopamine-Mitochondria Crosstalk

Dopamine metabolism and mitochondrial function are reciprocally linked in a vicious cycle of redox amplification. Cytosolic dopamine undergoes enzymatic oxidation via MAO-B, releasing hydrogen peroxide, while spontaneous auto-oxidation generates semiquinones and dopamine-o-quinone species that directly damage mitochondrial proteins (Hwang, 2013; Tan, Wu, Chen, & Feng, 2022). These oxidative products disrupt complex I and III subunits, increasing electron leak and superoxide generation (Lin & Beal, 2006; Exner et al., 2012). In turn, mitochondrial impairment heightens reactive oxygen species (ROS) flux, accelerating dopamine oxidation. Studies using midbrain neuronal cultures show that mild inhibition of complex I suffices to elevate cytosolic dopamine oxidation within hours (Dong-Chen et al., 2023). Thus, dopamine and mitochondria are mutually dependent oxidant sources: Dopamine oxidation weakens mitochondrial energetics, while mitochondrial ROS enhance dopamine's redox instability.

Iron as a Catalytic Bridge Between Systems

Iron serves as a catalytic bridge uniting dopamine metabolism and mitochondrial stress. It is physiologically indispensable as a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, but excess iron shifts from catalytic necessity to toxic catalysis (Dexter et al., 1989). Elevated nigral iron promotes Fenton chemistry, converting hydrogen peroxide to hydroxyl radicals that indiscriminately oxidize dopamine, lipids, and mitochondrial membranes (Dong-Chen et al., 2023). Damaged mitochondrial membranes then release additional free iron from iron-sulfur clusters, magnifying the catalytic pool (Li, Wang, Huang, & Gong, 2024). Conversely, dopamine quinones can chelate iron and alter ferritin stability, aggravating labile iron accumulation (Chang & Chen, 2020). This biochemical reciprocity explains the spatial coincidence of high iron concentration and dopamine turnover in the substantia nigra: Both fuel each other's oxidative potential.

Protein Misfolding as Amplifier and Consequence

Œ±-Synuclein, the major component of Lewy bodies, acts as both a sensor and amplifier of oxidative and metal stress. Dopamine-derived quinones covalently modify cysteine and lysine residues on Œ±-synuclein, promoting Œ≤-sheet-rich oligomer formation (Hwang, 2013; Zhou et al., 2023). These oligomers interfere with vesicular dopamine storage, raising cytosolic dopamine levels and perpetuating its oxidation (Chang & Chen, 2020). Simultaneously, Œ±-synuclein aggregates impair mitochondrial transport along axons and interact with complex I subunits, further suppressing ATP synthesis (Exner et al., 2012). Iron binding to Œ±-synuclein accelerates its fibrillization (Li et al., 2024), while oxidized lipids such as HNE stabilize toxic oligomers (Qin et al., 2007) Therefore, protein misfolding is not a downstream epiphenomenon but an integral node in the oxidative network-linking redox chemistry, metal imbalance, and mitochondrial compromise.

Network-Level Dynamics and Feedforward Convergence

When considered together, these subsystems constitute a closed feedback circuit:

- Dopamine oxidation produces ROS and quinones that impair mitochondria.

- Mitochondrial dysfunction increases ROS and releases labile iron.
- Iron catalysis accelerates lipid peroxidation and dopamine oxidation.
- Protein misfolding impairs vesicular dopamine storage and mitochondrial function.
- Inflammatory activation from cell debris amplifies ROS/RNS production and suppresses antioxidant responses.

This cascading system operates as a biochemical amplifier in which small perturbations-environmental toxins, genetic mutations, or aging-related antioxidant decline can tip the balance toward chronic oxidative stress (Chakrabarti & Bisaglia, 2023; Uruno & Yamamoto, 2023). The interplay between these nodes also underlies clinical heterogeneity: Individuals with predominant mitochondrial or iron pathology often show faster motor decline, whereas those with early Œ±-synuclein accumulation exhibit more pronounced non-motor symptoms such as mood dysregulation and sleep disturbance (Chaudhuri & Schapira, 2009; Poewe et al., 2017).

Antagonistic and Compensatory Interactions

Although these pathways largely reinforce each other, certain antagonistic or compensatory dynamics exist. Neuromelanin formation from dopamine oxidation can initially sequester redox-active metals, temporarily buffering iron toxicity (Chang & Chen, 2020). Similarly, mild mitochondrial uncoupling can reduce superoxide production by lowering electron leak (Lin & Beal, 2006). However, these defenses are finite: As neuromelanin becomes saturated and damaged mitochondria accumulate due to impaired mitophagy, the compensatory balance collapses, converting protective feedback into destructive feedforward loops (Exner et al., 2012). The temporal sequencing of these shifts-compensation, saturation, decompensation-likely determines the rate of neuronal death and the onset of motor symptoms (Dong-Chen et al., 2023).

Systems-Level Perspective and Clinical Correlates

From a systems-neuroscience viewpoint, the convergence of oxidative, metabolic, and proteostatic stress distorts basal ganglia network dynamics. Loss of dopaminergic modulation in the striatum skews the balance between the direct and indirect motor pathways, producing bradykinesia and rigidity (Albin, Young, & Penney, 1989). Simultaneously, oxidative injury extends to mesolimbic and mesocortical projections, contributing to depression, apathy, and executive dysfunction (Chaudhuri & Schapira, 2009). Progressive astroglial and microglial activation propagate these alterations beyond the substantia nigra, explaining the widespread but patterned clinical evolution of PD (Chakrabarti & Bisaglia, 2023).

Future Directions and Conceptual Implications

This multi-axis model suggests that Parkinson's disease should be conceptualized not as a linear neurodegenerative process but as a systems-level redox disorder in which dopamine chemistry, mitochondrial bioenergetics, iron catalysis, and protein homeostasis are dynamically intertwined. Targeting one component in isolation may produce transient benefit yet fail to halt the overall cascade because the remaining pathways sustain oxidative drive (Uruno & Yamamoto, 2023; Li et al., 2024). Future research must therefore map the temporal evolution and spatial hierarchy of these interactions identifying which feedback loops activate earliest and which remain modifiable in later stages. Integrative approaches combining molecular imaging, redox proteomics, and computational modeling may redefine early intervention strategies and transform PD from a relentlessly progressive disease into a condition amenable to network-level regulation.

Conclusion

Parkinson's disease epitomizes the convergence of dopamine oxidation, mitochondrial dysfunction, iron dysregulation, and proteostatic failure into a unified redox network that gradually destabilizes neuronal integrity. These interdependent processes transform transient metabolic stress into chronic oxidative disequilibrium. Within dopaminergic neurons, dopamine-derived quinones and MAO-B-generated hydrogen peroxide directly impair mitochondrial function, while mitochondrial ROS and released iron amplify dopamine oxidation. Œ±-synuclein aggregation further disrupts vesicular storage and proteostasis, creating an environment where oxidative stress, bioenergetic failure, and protein misfolding perpetuate one another. The resulting feedback architecture explains both the selective vulnerability of substantia nigra neurons and the heterogeneous clinical profile encompassing motor and non-motor symptoms.

Conceptually, PD should be understood as an interactive and self-organizing degenerative system, in which cellular defense mechanisms—such as neuromelanin formation, glutathione buffering, and mitophagy—initially compensate but ultimately succumb to cumulative stress. This framework encourages a shift in focus from identifying single pathogenic "triggers" to understanding how multiple redox, metabolic, and inflammatory axes intersect over time. By integrating these perspectives, the field moves closer to a holistic model of neurodegeneration that accounts for both molecular complexity and network-level coherence. Such a systems view does not merely refine the pathophysiological narrative of Parkinson's disease but also establishes the conceptual foundation for future multidimensional research and therapeutic innovation.

References

Albin, R. L., Young, A. B., & Penney, J. B. (1989). The functional anatomy of basal ganglia disorders. *Trends in Neurosciences, 12*(10), 366-375. Retrieved from https://doi.org/10.1016/0166-2236(89)90074-X

Chakrabarti, S., & Bisaglia, M. (2023). Oxidative stress and neuroinflammation in Parkinson's disease: The role of dopamine oxidation products. *Antioxidants, 12*(4), 955. Retrieved from https://doi.org/10.3390/antiox12040955

Chang, K.-H., & Chen, C.-M. (2020). The role of oxidative stress in Parkinson's disease. *Antioxidants, 9*(7), 597. Retrieved from https://doi.org/10.3390/antiox9070597

Chaudhuri, K. R., & Schapira, A. H. V. (2009). Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. *The Lancet Neurology, 8*(5), 464-474. Retrieved from https://doi.org/10.1016/S1474-4422(09)70068-7

Devos, D., Labreuche, J., Rascol, O., Corvol, J.-C., Duhamel, A., Guyon-Delannoy, P., … FAIR-PARK II Study Group. (2022). Trial of deferiprone in Parkinson's disease (FAIR-PARK II). *The New England Journal of Medicine, 387*(22), 2045-2055. Retrieved from https://doi.org/10.1056/NEJMoa2209254

Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1989). Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. *Journal of Neurochemistry, 52*(6), 1830-1836. Retrieved from https://doi.org/10.1111/j.1471-4159.1989.tb07264.x

Dias, V., Junn, E., & Mouradian, M. M. (2013). The role of oxidative stress in Parkinson's disease. *Journal of Parkinson's Disease, 3*(4), 461-491. Retrieved from https://doi.org/10.3233/JPD-130230

Dong-Chen, X., Liu, R., Zhang, H., Zhou, X., Zhao, L., Chen, T., & Wang, J. (2023). Signaling pathways in Parkinson's disease: Molecular mechanisms and therapeutic targets. *Signal Transduction and Targeted Therapy, 8*, 73. Retrieved from https://doi.org/10.1038/s41392-023-01353-3

Exner, N., Lutz, A.-K., Haass, C., & Winklhofer, K. F. (2012). Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and pathophysiological consequences. *The EMBO Journal, 31*(14), 3038-3062. Retrieved from https://doi.org/10.1038/emboj.2012.170

Hwang, O. (2013). Role of oxidative stress in Parkinson's disease. *Experimental Neurobiology, 22*(1), 11-17. Retrieved from https://doi.org/10.5607/en.2013.22.1.11

Li, J., Wang, Y., Huang, J., & Gong, D. (2024). Knowledge mapping of ferroptosis in Parkinson's disease: A bibliometric analysis (2012-2023). *Frontiers in Aging Neuroscience, 16*, 1433325. Retrieved from https://doi.org/10.3389/fnagi.2024.1433325

Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature, 443*(7113), 787-795. Retrieved from https://doi.org/10.1038/nature05292

Majkutewicz, I. (2022). Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases. *European Journal of Pharmacology, 926*, 175025. Retrieved from https://doi.org/10.1016/j.ejphar.2022.175025

Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., … Lang, A. E. (2017). Parkinson disease. *Nature Reviews Disease Primers, 3*, 17013. Retrieved from https://doi.org/10.1038/nrdp.2017.13

Qin, Z., Hu, D., Han, S., Reaney, S. H., Di Monte, D. A., & Fink, A. L. (2007). Effect of 4-hydroxy-2-nonenal modification on α-synuclein aggregation. *Journal of Biological Chemistry, 282*(8), 5862-5870. Retrieved from https://doi.org/10.1074/jbc.M608126200

Tan, Y. Y., Wu, L., Chen, Z., & Feng, J. (2022). Monoamine oxidase-B inhibitors for the treatment of Parkinson's disease: Clinical perspectives and challenges. *Journal of Parkinson's Disease, 12*(2), 477-493. Retrieved from https://doi.org/10.3233/JPD-212976

Uruno, A., & Yamamoto, M. (2023). The KEAP1-NRF2 system and neurodegenerative diseases. *Antioxidants & Redox Signaling, 38*(13), 974-988. Retrieved from https://doi.org/10.1089/ars.2023.0234

Zhou, Z. D., Tan, E. K., & Lim, T. M. (2023). Role of dopamine in the pathophysiology of Parkinson's disease: An updated synthesis. *Translational Neurodegeneration, 12*, 44. Retrieved from https://doi.org/10.1186/s40035-023-00378-6